..., instructions or products referred to in the content or advertisements. Hepatitis C Hepatitis B Coinfection DAA treatment HBV reactivation Hepatitis Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the most common causes of chronic liver disease [1]. The prevalence of HBV...

...Ahmed Al-Khazraji; Ishan Patel; Mohammed Saleh; Amar Ashraf; Joseph Lieber; Raza Malik Background and Aims: Chronic hepatitis C (CHC) viral infection has a major impact on our health care system. The emergence of direct-acting antiviral agents (DAA) has made treatment simple (oral), efficacious...

..., instructions or products referred to in the content or advertisements. Hepatitis C Hepatocellular carcinoma Direct antivirals Tumor recurrence Liver cirrhosis Hepatitis C virus (HCV) is a well-known cause of liver cirrhosis which in turn culminates in hepatocellular carcinoma (HCC...

...Sabela Lens; Sergio Rodriguez-Tajes; Laura-Patricia Llovet; Francisco Maduell; Maria-Carlota Londoño Background: There is a strong relationship between hepatitis C virus (HCV) infection and the kidney. Approximately 10-16% of the patients with HCV infection develop renal disease, and the prevalence...

...Martín Bonacci; Sabela Lens; Zoe Mariño; Xavier Forns Until recently, the combination of PEG-interferon and ribavirin (RBV) was the main treatment for all genotypes of chronic hepatitis C virus (HCV) infection. Sustained virological response (SVR) rates varied significantly across patient subgroups...

...Gisa Gerold; Thomas Pietschmann Hepatitis C virus (HCV) is a highly variable plus-strand RNA virus of the family Flaviviridae . Viral strains are grouped into six epidemiologically relevant genotypes that differ from each other by more than 30% at the nucleotide level. The variability of HCV allows...

... consisted of 547 patients identified with the first event of HCC, the second cohort included 176 HCC patients, and the third 127 patients with chronic hepatitis C (CHC). Results: Male patients were found to have HCC more frequently than female patients in cases of non-cirrhotic liver (p = 0.0030 by the χ 2...

... (PEG-IFN) + ribavirin (RBV) combination therapy is the current standard of care for chronic hepatitis C. However, more than half of the patients cannot achieve sustained viral response (SVR). In Japan, the clinical benefit of retreatment with PEG-IFN + RBV combination retreatment is still unknown...

...Sebastian Lunemann; Verena Schlaphoff; Markus Cornberg; Heiner Wedemeyer Hepatitis C is caused by infection with the hepatitis C virus (HCV), a single-stranded RNA virus, which was first described in 1989. Hepatitis C is a major global health burden with approximately 150 million people chronically...

... globally and is associated with insulin resistance, steatosis and a low-grade systemic inflammatory state. These metabolic factors have a synergistic role in the natural history and treatment outcomes related to chronic liver disease. This is characterized best in chronic hepatitis C where steatosis...

...Robert Fontana Dose-dependent, reversible neuropsychiatric toxicity is reported in up to 30–40% of chronic hepatitis C patients treated with 6–12 months of interferon-α or interferon-α plus ribavirin combination therapy. Although risk factors remain poorly defined, neuropsychiatric side effects may...

...B.S. Anand; Maria Velez Background: Patients with alcoholic liver disease have a high prevalence of hepatitis C virus (HCV) infection. Several workers have shown that HCV-infected alcoholics have more severe biochemical and histological evidence of liver disease than anti-HCV-negative patients. One...